CLAIMS

1. A peptide consisting of SEQ ID No. 28, or a pharmaceutical acceptable salt thereof.

2. The peptide according to Claim 1, wherein said peptide includes non-peptide bonds.

3. An in vitro method for producing activated cytotoxic T lymphocytes (CTL), the method comprising contacting in vitro CTL with antigen loaded human class I MHC molecules expressed on the surface of a suitable antigen-presenting cell or an artificial construct mimicking an antigen-presenting cell for a period of time sufficient to activate said CTL in an antigen specific manner, wherein said antigen is a peptide according to claim 1.

4. An activated cytotoxic T lymphocyte (CTL), produced by the method according to claim 3, that selectively recognises a cell which aberrantly expresses a polypeptide comprising an amino acid sequence given in claim 1.

5. An antibody that specifically recognizes the peptide according to claims 1 or 2, or said peptide when bound to an MHC molecule.

6. A T-cell receptor that is reactive with an HLA ligand consisting of the amino acid sequence of SEQ ID No. 28.

7. A nucleic acid, encoding a peptide according to any one of claims 1 or 2, an activated cytotoxic T lymphocyte according to claim 4, an antibody according to claim 5, or a T cell receptor according to claim 6, optionally linked to a heterologous promoter sequence, or an expression vector expressing said nucleic acid.

8. A host cell comprising the nucleic acid or the expression vector according to claim 7.

9. The host cell according to claim 8, wherein said host cell is an antigen presenting cell or a dendritic cell.

10. A peptide according to any one of claims 1 or 2, an activated cytotoxic T lymphocyte according to claim 4, an antibody according to claim 5, a T cell receptor according to claim 6, the nucleic acid or the expression vector according to claim 7, or the cell according to claim 8 or 9, for use in the treatment of a disease.

11. The peptide, the activated cytotoxic T lymphocyte, the antibody, the T cell receptor, the nucleic acid or the expression vector, or the cell for use according to claim 10, wherein said disease is cancer, preferably in form of a pharmaceutical composition, e.g. vaccine.

12. The pharmaceutical composition for use according to claim 11, wherein said cancer is selected from astrocytoma, pilocytic astrocytoma, dysembryoplastic neuroepithelial tumor, oligodendrogliomas, ependymoma, glioblastoma multiforme, mixed gliomas, oligoastrocytomas, medulloblastoma, retinoblastoma, neuroblastoma, germinoma, teratoma, gangliogliomas, gangliocytoma, central gangliocytoma, primitive neuroectodermal tumors (PNET, e.g. medulloblastoma, medulloepithelioma, neuroblastoma, retinoblastoma, ependymoblastoma), tumors of the pineal parenchyma (e.g. pineocytoma, pineoblastoma), ependymal cell tumors, choroid plexus tumors, neuroepithelial tumors of uncertain origin (e.g. gliomatosis cerebri, astroblastoma), glioblastoma prostate tumor, breast cancer, esophageal cancer, colorectal cancer, clear cell renal cell carcinoma, lung cancer, CNS, ovarian, melanoma pancreatic cancer, squamous cell carcinoma, leukemia medulloblastoma, colon, rectum, stomach, kidney, lung, pancreatic, prostate, and skin cancer.

13. A kit comprising:

(a) a container comprising a pharmaceutical composition containing a peptide according to any one of claims 1 or 2, an activated cytotoxic T lymphocyte according to claim 4, an antibody according to claim 5, a T cell receptor according to claim 6, the nucleic acid or the expression vector according to claim 7, or the cell according to claim 8 or 9, in solution or in lyophilized form;

(b) a second container containing a diluent or reconstituting solution for the lyophilized formulation; and

(c) optionally, instructions for (i) use of the solution or (ii) reconstitution and/or use of the lyophilized formulation.

14. The kit according to claim 13, further comprising:

(d) at least one or more peptides selected from the group consisting of SEQ ID No. 1 to SEQ ID No. 27, and SEQ ID No. 29 to SEQ ID No. 131.